Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Multi-site medical record review for validation of intentional self-harm coding in emergency departments - Gabella BA, Hume B, Li L, Mabida M, Costich J.
BACKGROUND: Codes in the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), are used for injury surveillance, including surveillance of intentional self-harm, as they appear in administrative billing records. This ...
Source: SafetyLit - June 9, 2022 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Investor Update - June 9, 2022 Category: Pharmaceuticals Source Type: news

U.S. FDA approves Foundation Medicine ’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
FoundationOneCDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solidtumours for whom treatment withRozlytrek may be appropriateThis approval marks the first and only companion diagnostic indication forRozlytrek, and another important milestone intumour-agnostic approaches for people living with rare cancersRoche is a leader in drivingpersonalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug developmentBasel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvantTecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive careTecentriq is now the firstand only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeToday ’s approval marksTecentriq ’s sixth lung cancer indication in EuropeBasel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adu...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news

Sex differences in sepsis hospitalisations and outcomes in older women and men: A prospective cohort study
Purpose: To examine the association of sex with hospitalisation due to sepsis and related outcomes. Methods: Prospective cohort study of 264,678 adults, average age 62.7 years at recruitment (2006 –2009) in Australia. Participants were followed for sepsis hospitalisation identified using the International Classification of Diseases coding. Outcomes included sexdifferences in the risk of an incident sepsis hospitalisation, mortality, length of ICU and hospital stay and readmissions during th e following year.
Source: Current Awareness Service for Health (CASH) - June 6, 2022 Category: Consumer Health News Source Type: news

Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Application of a machine learning-based decision support tool to improve an injury surveillance system workflow - Catchpoole J, Nanda G, Vallmuur K, Nand G, Lehto M.
Background Emergency department (ED)-based injury surveillance systems across many countries face resourcing challenges related to manual validation and coding of data. OBJECTIVE This paper describes the evaluation of a machine learning-based Decis...
Source: SafetyLit - June 3, 2022 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

How does Injury Severity Score Derived from ICDPIC utilizing ICD-10-CM codes perform compared to Injury Severity Score derived from TQIP? - Wan V, Reddy S, Thomas A, Issa N, Posluszny J, Schwulst S, Shapiro M, Alam H, Bilimoria KY, Stey AM.
BACKGROUND: Injury severity score (ISS) is a measurement of injury severity based on the Abbreviated Injury Scale (AIS). Due to the difficulty and expense of AIS coding, there have been recent efforts in mapping ISS from administrative International Classi...
Source: SafetyLit - June 3, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BEERSE, BELGIUM, 26 May 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license a...
Source: Johnson and Johnson - May 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Maryland ’s Statewide Value-Based Payment Models Benefit both Healthcare Providers and Patients
By shifting away from fee-for-service, the state encouraged collaboration between hospitals and physicians to improve care and lower costs Maryland “leads the way” in value-based payment reform, according to a series of articles published in Health Affairs. “The evidence is clear,” the article declares, “Maryland’s application of uniform prices within global budgets lowers total care […] The post Maryland’s Statewide Value-Based Payment Models Benefit both Healthcare Providers and Patients appeared first on Dark Daily.
Source: Dark Daily - May 23, 2022 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Coding, Billing, and Collections Compliance, Legal, and Malpractice Laboratory Management and Operations Laboratory News Managed Care Contracts & Payer Reimbursement anatomic pathology Center for Medicare and Medicaid Innovation centers for Source Type: news

Los Angeles Reaches $26 Million Settlement with Sameday Health and its Contract Doctor Over Alleged Phony COVID-19 Lab Test Results That Put Patients at Risk and Cost Insurers Millions
Company was accused of manipulating clinical laboratory reports from previous COVID-19 tests to forge new results, and sending “negative” test results to patients even though their tests had never been completed National COVID-19 testing chain Sameday Health (a.k.a., Sameday Technologies) will pay $22.5 million—and its contracted doctor an additional $3.9 million—to settle a case with […] The post Los Angeles Reaches $26 Million Settlement with Sameday Health and its Contract Doctor Over Alleged Phony COVID-19 Lab Test Results That Put Patients at Risk and Cost Insurers Millions appeared first on Dark Daily.
Source: Dark Daily - May 20, 2022 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Coding, Billing, and Collections Compliance, Legal, and Malpractice Laboratory Management and Operations Laboratory News Laboratory Pathology Laboratory Testing anatomic pathology clinical laboratory COVID-19 D. Shawn Burkley JD Dark D Source Type: news

National Medical Billing Services acquires New Jersey-based billing company
A Chesterfield-based health care billing company has acquired a New Jersey-based provider of medical billing and coding services.
Source: bizjournals.com Health Care News Headlines - May 17, 2022 Category: Health Management Authors: Diana Barr Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20